Cross-reactive immune responses against Mycobacterium bovis BCG in mice infected with non-tuberculous mycobacteria belonging to the MAIS-group

Scandinavian Journal of Immunology

Volumn 46, Issue 1, 1997, Pages 16-26

  Lozes, E ^a   Denis, O ^a   Drowart, A ^b   Jurion, F ^a   Palfliet, K ^a   Vanonckelen, A ^a   De Bruyn, J ^c   De Cock, M ^b   Van Vooren, J P ^b   Huygen, K ^a  

^a PASTEUR INSTITUTE OF BRUSSELS   (Belgium)

^b ERASME HOSPITAL   (Belgium)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; GAMMA INTERFERON; INTERLEUKIN 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BCG VACCINATION; CONTROLLED STUDY; CROSS REACTION; IMMUNE RESPONSE; INTRAVENOUS DRUG ADMINISTRATION; MYCOBACTERIOSIS; MYCOBACTERIUM AVIUM; MYCOBACTERIUM BOVIS; MYCOBACTERIUM INTRACELLULARE; MYCOBACTERIUM SCROFULACEUM; NONHUMAN; PRIORITY JOURNAL;

EID: 8544219679     PISSN: 03009475     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-3083.1997.d01-99.x     Document Type: Article

References (33)

1. Bloom BR, Murray CJL. Tuberculosis: commentary on a reemergent killer. Science 1992;257:1055-64.
2. Bloom BR, Fine PEM. The BCG experience: implications for future vaccines against tuberculosis. In: Bloom BR ed. Tuberculosis: Pathogenesis, Protection and Control. Washington: ASM Press, 1994;531-57.
3. Colditz GA, Brewer TF, Berkey CS et al. Efficay of BCG vaccine in the prevention of tuberculosis. JAMA 1994;271:698-702.
4. Fine PEM. Variation in protection by BCG: implications of and for heterologous immunity. Lancet 1995;346:1339-45.
5. Nightingale SD, Byrd LT, Southern PM, Jockusch JD, Cal SX, Wynne BA. Incidence of Mycobacterium avium-intracellulare complex bacteraemia in human immunodeficiency virus-positive patients. J Infect Dis 1992;165:1082-5.
6. Youmans GP, Parlett RC, Youmans AS. The significance of the response of mice to immunization with viable unclassified mycobacteria. Am Rev Respir Dis 1979;119:107-59.
7. Palmer CE, Long MW. Effects of infection with atypical mycobacteria on BCG vaccination and tuberculosis. Am Rev Respir Dis 1966;94:553-68.
8. Andersen P. Effective vaccination of mice against Mycobacterium tuberculosis infection with a soluble mixture of secreted mycobacterial proteins. Infect Immun 1994;62:2536-44.
9. Horwitz MA, Lee BWE, Dillon BJ, Harth G. Protective immunity against tuberculosis induced by vaccination with major extracellular proteins of Mycobacterium tuberculosis. Proc Natl Acad Sci USA 1995;92:1530-4.
10. Huygen K, Abramowicz D, Vandenbussche P et al. Spleen cell cytokine secretion in Mycobacterium bovis BCG infected mice. Infect Immun 1992;60:2880-6.
11. De Bruyn J, Bosmans R, Turneer M et al. Purification, partial characterization and identification of a skin-reactive protein antigen of M. bovis BCG. Infect Immun 1987;55:245-52.
12. De Bruyn J, Huygen K, Bosmans R et al. Purification, characterization and identification of a 32 kDa protein antigen of Mycobacterium bovis BCG. Microb Pathol 1987;2:351-66.
13. Huygen K, Drowart A, Harboe M, ten Berg R, Cogniaux J, Van Vooren JP. Influence of genes from the major histocompatibility complex on the antibody repertoire against culture filtrate antigens in mice infected with live Mycobacterium bovis BCG. Infect Immun 1993;61:2687-93.
14. Huygen K, Lozes E, Gilles B et al. Mapping of TH1 T cell epitopes on major secreted antigen 85A in mice infected with live Mycobacterium bovis BCG. Infect Immun 1992;62:363-70.
15. Drowart A, De Bruyn J, Huygen K et al. Isoelectrophoretic characterization of protein antigens present in mycobacterial culture filtrates and recognized by monoclonal antibodies directed against the M. bovis BCG antigen 85. Scand J Immunol 1992;36:697-702.
16. Lefèvre P, Braibant M, De Wit L et al. Three different putative phosphate transport receptors are encoded by the Mycobacterium tuberculosis genome and are present at the surface of Mycobacterium bovis BCG. J Bact 1997;179:2900-6.
17. Thole JER, Van Schooten WCA, Keulen WJ et al. Use of recombinant antigens expressed in E. coli to map B-cell and T-cell epitopes on the immunodominant 65-kD protein of Mycobacterium bovis BCG. Infect Immun 1988;56:1633-40.
18. Yoshida A, Koide Y, Uchijima M, Yoshida TO. Dissection of strain difference in acquired protective immunity against Mycobacterium bovis Calmette-Guérin bacillus (BCG). J Immunol 1995;155:2057-66.
19. Saunders BM, Cheers C. Intranasal infection of beige mice with Mycobacterium avium complex: Role of neutrophils and natural killer cells. Infect Immun 1996;64:4236-41.
20. Orme IM, Collins FM. Efficacy of Mycobacterium bovis BCG vaccination in mice undergoing prior pulmonary infection with atypical mycobacteria. Infect Immun 1984;44:28-32.
21. Pedrosa J, Florido M, Kunze ZM et al. Characterization of the virulence of Mycobacterium avium complex (MAC) isolates in mice. Clin Exp Immunol 1994;98:210-16.
22. Appelberg R, Castro AG, Pedrosa J, Silva RA, Orme IM, Minoprio P. The role of gamma interferon and tumor necrosis factor-alpha during the T cell independent and dependent phases of Mycobacterium avium infection. Infect Immun 1994;62:3962-71.
23. Wiker HG, Harboe M. The antigen 85 complex: A major secretion product of Mycobacterium tuberculosis. Microbiol Rev 1992; 56:648-61.
24. Joliff G, Mathieu L, Hahn V et al. Cloning and nucleotide sequence of the csp1 gene encoding PS1, one of the two major secreted proteins of Corynebacterium glutamicum: the deduced N-terminal region of PSI is similar to the Mycobacterium tuberculosis antigen 85 complex. Mol Microbiol 1992;6:2349-62.
25. Peake P, Gooley A, Britton WJ. Mechanism of interaction of the 85B secreted protein of Mycobacterium bovis with fibronectin. Infect Immun 1993;61:4828-34.
26. Belisle JT, Sievert T, Takayama K, Besra GS. Identification of a mycolyltransferase from Mycobacterium tuberculosis and the coincident definition of the physiological function of antigen 85B. Thirtieth US-Japan Conference on Tuberculosis and Leprosy. 1995;75-8.
27. Launois P, DeLeys R, Niang MND et al. T cell epitope mapping of the major secreted mycobacterial antigen Ag85 A in tuberculosis and leprosy. Infect Immun 1994;62:3679-87.
28. Silver RF, Wallis RS, Ellner JJ. Mapping of T cell epitopes of the 30 kDa α antigen of Mycobacterium bovis strain Bacillus Calmette-Guérin in purified protein derivative (PPD) positive individuals. J Immunol 1995;154:4665-74.
29. Roche PW, Peake PW, Billman-Jacobe H, Doran T, Britton WJ. T cell determinants and antibody binding sites on the major secretory protein MPB59 of Mycobacterium bovis. Infect Immun 1994; 62:5319-26.
30. Huygen K, Content J, Denis O et al. Immunogenicity and protective efficacy of a tuberculosis DNA vaccine. Nature Medicine 1996; 2:893-8.
31. Lozes E, Huygen K, Content J et al. Immunogenicily and efficacy of a tuberculosis DNA vaccine encoding the components of the secreted antigen 85 complex. Vaccine 1997;15:in press.
32. Källenius G, Hoffner SE, Svenson SB. Does vaccination with Bacille Calmette-Guérin protect against AIDS? Rev Infect Dis 1989;11:349-51.
33. Grange JM. Is the incidence of AIDS-associated Mycobacterium avium-intracellulare disease affected by previous exposure to BCG M. tuberculosis or environmental mycobacteria? Tuberc Lung Dis 1994;75:234-6.